Close Menu

NEW YORK – The US Food and Drug Administration on Wednesday converted an earlier accelerated approval for lorlatinib (Lorbrena) to regular approval, allowing drugmaker Pfizer to market its ALK inhibitor to newly diagnosed, metastatic ALK-positive non-small cell lung cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.